FDA Rubber Stamps Experimental NOVAVAX 2024-2025 COVID-19 Vaccine with Zero Clinical Data

by James Lyons-Weiler, PhD, Popular Rationalism, ©2024 

(Aug. 31, 2024) — The U.S. Food and Drug Administration (FDA) recently authorized an updated version of the Novavax COVID-19 vaccine under Emergency Use Authorization (EUA). This decision has raised significant concerns due to the absence of new clinical trial data supporting the updated vaccine’s safety and efficacy. Traditionally, vaccine approval follows a rigorous process, requiring comprehensive clinical trials—usually spanning several phases—designed to establish safety, efficacy, and overall benefit-risk balance. These trials involve extensive testing in diverse populations, rigorous data collection, and thorough analysis of outcomes to ensure that the vaccine performs as expected across different demographics and scenarios.

According to the FDA:

“Individuals 12 years of age and older who have never been vaccinated with any COVID-19 vaccine are eligible to receive two doses of this updated vaccine, 3 weeks apart.

• Individuals who have been vaccinated only with one dose of any Novavax COVID-19 vaccine are eligible to receive one dose of the updated Novavax COVID-19 vaccine at least 3 weeks after the previous dose.  
• Those who have been vaccinated with a prior formula of a COVID-19 vaccine from another manufacturer or with two or more doses of a prior formula of the Novavax COVID-19 vaccine are eligible to receive a single dose of the updated Novavax COVID-19 vaccine at least 2 months after the last dose of a COVID-19 vaccine.”

This assessment, according to the FDA, was based on

“The FDA assessed manufacturing and nonclinical data to support the change to the 2024-2025 formula.”

The FDA tries to justify this lack of oversight with one sentence: “The updated vaccine is manufactured using a similar process as previous formulas of this vaccine.”

The EUA process, introduced to expedite vaccine availability during public health emergencies, allows for a more streamlined approach. Under an EUA, the FDA requires that a product “may be effective” and that the known and potential benefits outweigh the known and potential risks, allowing for authorization based on less complete data than would typically be required for full approval.

The updated Novavax vaccine, targeting newer variants such as the Omicron variant JN.1 strain, was authorized without new phase III clinical trials demonstrating its safety and efficacy in humans. Instead, the authorization relied on immune response data extrapolated from earlier studies of the original Novavax vaccine. These data primarily measured antibody responses rather than clinical outcomes like the prevention of COVID-19 cases, hospitalizations, or deaths. This approach raises several red flags, particularly given the evolving nature of the virus and the distinct immunological challenges posed by new variants.

Such reliance on immune markers rather than real-world effectiveness data represents a significant deviation from the rigorous standards typically employed in vaccine development and approval. Moreover, it suggests a gap in the current regulatory framework’s ability to adapt to the unique demands of rapidly evolving pathogens and variant-specific immunological responses. By authorizing this updated vaccine based on incomplete data, the FDA has set a precedent that may have far-reaching implications for public trust in vaccine safety and efficacy.

The decision also highlights the urgent need for transparency in the FDA’s decision-making process. It is not entirely clear what specific data were considered sufficient to justify the authorization, nor how potential risks, such as those associated with antibody-dependent enhancement (ADE) and other adverse events, were weighed against the anticipated benefits. The lack of clarity and detailed public disclosure surrounding the authorization process for the updated Novavax vaccine has fueled skepticism and concern among healthcare professionals, scientists, and the general public.

The authorization of the updated Novavax vaccine under EUA, without fresh clinical data, reflects the lax standards of the US HHS for vaccine approval and does little to improve the FDA’s credibility in the eyes of the vaccine-wary public.

Read the rest here.